Announced Date: 2025-03-24 (March 24, 2025)
Asset Name: UBT251
Licensor: United Laboratories (The United Laboratories International Holdings Limited (TUL) and the wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), China)
Licensee (Buyer): Novo Nordisk（Novo Nordisk A/S）
Asset Target: GLP-1/GIP/GCG triple receptor agonist
（ glucagon-like peptide-1，glucose-dependent insulinotropic polypeptide， glucagon）
Asset Modality: Small Molecule，long-acting synthetic peptide
Current Stage: Early-stage clinical development , phase 1b, phase 2 trial in China
Scope of Authority:
Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251.
United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan.
Deal Detail:
Upfront payment of $200 million;
Milestone payments up to $1.8 billion;
Total up to $2 billion.
Additional royalties based on net sales in the licensed territories.
Link:
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Good article